Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in advanced carcinoid and pancreatic neuroendocrine tumors
NCT02575300Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Oct 2015
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in Carcinoid Tumor (CT), Pancreatic neuroendocrine tumor (PanNET), sponsored by Moffitt Cancer Center. Started Oct 2015; status: completed.
02
Drugs
ibrutinib
03
Conditions
Carcinoid Tumor (CT)Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT02575300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02575300.